Cisplatin 75 mg / m2 d1 with Pemetrexed 500 mg / m2 d1 every 3 weeks for 6 cycles followed (in responding or stable patients) by Pemetrexed 500 mg / m2 every 3 weeks, until progression or unacceptable toxicity, Carboplatin AUC 6 d1 plus Paclitaxel 200 mg/m2 d1 and Bevacizumab 15 mg/kg every 3 weeks for 6 cycles followed in stable or responding patients by Bevacizumab 15 mg/kg every 3 weeks, until progression or unacceptable toxicity. The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments. TAPUR Study, Terms of Use | Privacy Policy | The OVID study is conducted as a multicentre open-label superiority … † The following investigators are members of the Gruppo Oncologico dell'Italia Meridionale and are coauthors of the article: Severino Montemurro, M.D. ASCO Author Services Bernhard Gerber Bellinzona (CH) Walter Wuillemin Luzern (CH) Hepatology. The OVID study will demonstrate whether prophylactic-dose enoxaparin improves survival and reduces hospitalizations in symptomatic ambulatory patients aged 50 or older diagnosed with COVID-19, a novel viral disease characterized by severe systemic, pulmonary, and vessel inflammation and coagulation activation. It is assumed that: Choosing to participate in a study is an important personal decision. From the Oncology Institute, Bari; University; La Maddalena Hospital; M. Ascoli Hospital, Palermo; Regina Elena Institute; La Sapienza University, Rome; Centro Oncologico; S. Luigi Hospital, Catania; Cardarelli Hospital, Naples; Ospedale Nord, Taranto; S. Carlo Hospital, Potenza; Cardarelli Hospital, Campobasso; G. Panico Hospital, Tricase, Italy, Professional English and Academic Editing Support, 2318 Mill Road, Suite 800, Alexandria, VA 22314, © 2021 American Society of Clinical Oncology. Read our, ClinicalTrials.gov Identifier: NCT01303926, Interventional Pasquale Perri & Claudio Botti. ASCO Connection Andrea De Gottardi Lugano (CH) Guido Stirnimann Bern (CH) Laboratory medicine. Division of Gynecological Oncology, Regina Elena National Cancer Institute, Rome, Italy. Institutions DOI: 10.1200/JCO.2005.07.113 Journal of Clinical Oncology To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. Epub 2014 Dec 9. JCO Clinical Cancer Informatics Edited by Saverio Cinieri, Giuseppe Colucci, Evaristo Maiello, S.G. Rotondo, Antonio Russo, Nicola Silvestris. Fallica, M.D. colucci@goim.it Learn more about the change. Bari (Italy) a difference of clinical interest) after initial 3 months of maintenance.EuroQ5D (EQ5D) questionnaire total score and EQ5D visual analog scale (VAS)are validated and very simple to be administered.The statistical hypothesis tests described above are performed with t-test for unpaired data (or equivalent non-parametric, pending verification of normality of distribution by Shapiro-Wilk test), with alpha error = 0.05 (2-sided). 22 2015 Jul;16(4):262-73. doi: 10.1016/j.cllc.2014.12.002. Cisplatin and pemetrexed combination or carboplatin, paclitaxel and bevacizumab are now considered as standard treatment in non-squamous cell lung carcinoma (NSCLC). ASCO Daily News Bari (Italy), Giuseppe Colucci MD, President, Gruppo Oncologico Italia Meridionale, about 20% of randomized patients experienced a progression of disease before the time of evaluation of the primary endpoint, and that, this eventuality was not significantly different between the two treatments. See the complete profile on LinkedIn and discover Giuseppe’s connections and jobs at similar companies. Giuseppe Colucci Lugano (CH) Pierre Fontana Geneva (CH) Lukas Graf St. Gallen (CH) Inga Hegemann Zurich (CH) Christian Heinis Lausanne (CH) Johanna Kremer Hovinga Bern (CH) ... Hemato-oncology. Conquer Cancer Foundation Reviewers Newest Articles 9 Department of Oncology, University Campus Bio-Medico of Rome, Rome, Italy. JCO Oncology Practice Free Web tutorialsIatros is a company founded in 2012 by former Roche Diagnostic International executives building on more than 20 years of experience in pre-clinical, clinical development, strategic marketing and scientific affairs and a unique international network with the clinical, academic and industrial communities Prophylactic use of anticoagulants is allowed; international normalized ratio (INR) should be <1.5 at study enrollment, History of thrombotic disorders within the last 6 months prior to entry History of hypertension, unless hypertension is well controlled study entry (≤150/90 mm Hg) and the patient is on a stable regimen of antihypertensive therapy. This Phase III trial compared the activity and toxicity of gemcitabine with or without cisplatin on a weekly schedule in patients with locally advanced and/or metastatic pancreatic adenocarcinoma. D’Agostino A, Caruso M, Chiarenza M, Aiello R, Fallica G e Girlando A. 23, no. National Cancer Institute "G. Pascale" Thoracic Dept. Giammarco Surico MD. Colucci G, GOIM, Gruppo Oncologico dell'Italia Meridionale, Bari., undefined... Home Research-feed Channel Rankings GCT THU AI TR Open Data Must Reading Research Feed Meeting Abstracts, About View Giuseppe Coluccino’s profile on LinkedIn, the world’s largest professional community. Keywords provided by Giuseppe Colucci MD, Gruppo Oncologico Italia Meridionale: Non-squamous Nonsmall Cell Neoplasm of Lung. (August 01, 2005) Search for more papers by this author. (Oncology Center, Catania); Giancarlo Pa-oletti, M.D. Barco S, Bingisser R, Colucci G, Frenk A, Gerber B, Held U, Mach F, Mazzolai L, Righini M, Rosemann T, Sebastian T, Spescha R, Stortecky S, Windecker S, Kucher N. Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial. Medical Oncology, IRCCS Ospedale Oncologico Giovanni Paolo II, Bari, Italy. Abdou Ben Tayeb – Andah Ayachifar. Permissions, Authors ASCO Meetings For general information, Learn About Clinical Studies. 7 Oncology Unit, San Pietro Fatebenefratelli Hospital, Rome, Italy. JCO Precision Oncology, ASCO Educational Book 4866-4875. Address reprint requests to Giuseppe Colucci, MD, Medical and Experimental Oncology Unit, Oncology Institute, Via Amendola 209, 70126 Bari, Italy; e-mail: colucci@goim.it. The ASCO Post Address for reprints: Giuseppe Colucci, M.D., Medical and Experimental Oncology Unit, Oncology Institute, Via Amendola 209, 70125 Bari, Italy; Fax: 39-080-5555483; E-mail; colucci@goim.it Received February 28, 2001; revision received Clin Lung Cancer. Both main registrative trials are considered positive because they reached their objectives, but within them, the Quality of Life (QoL) of patients was not detailed neither has represented as primary objective of the studies. Contact Us Hamzaoui Med Amine – Fi 7ouma 3arbi. Division of Surgery A, Regina Elena National Cancer Institute, Rome, Italy. Annals of Oncology – Vol 15 Supplement 2: A 43 2004 6th AIOM Bologna15. Talk with your doctor and family members or friends about deciding to join a study. Advertisers, Journal of Clinical Oncology The study aims primarily to verify the null hypothesis that between the two schemes under consideration there is no minimal interesting difference (MID) (i.e. Cookies. It is considered that, together with enhancements that are added to the knowledge of the biology of NSCLC, QoL may influence the therapeutic choice if one of the associations show to be better tolerated by the patient and favours an amelioration of his QoL. DOI: 10.1200/JCO.2005.07.113 Journal of Clinical Oncology - 6 Oncology Unit, Antonio Cardarelli Hospital, Naples, Italy. Archive Club career Early career. Cancer.Net, ASCO.org Gianfranco Filippelli. Giuseppe Colucci, Francesco Giotta & Agnese Latorre. UofT Libraries is getting a new library services platform in January 2021. Subscribers Patients should not have any prior history of hypertensive crisis or hypertensive encephalopathy, Serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease, as defined by the New York Heart Association Class III or IV, Serious concomitant systemic disorder (for example, active infection including human immunodeficiency virus) that, in the opinion of the investigator, would compromise the patient's ability to adhere to the protocol, Receiving concurrent administration of any other antitumor therapy, Have a second primary malignancy that is clinically detectable at the time of consideration for study enrollment, Have had a prior malignancy other than NSCLC, carcinoma in situ of the cervix, or nonmelanoma skin cancer, unless that prior malignancy was diagnosed and definitively treated at least 5 years previously with no subsequent evidence of recurrence. You have reached the maximum number of saved studies (100). Giuseppe Colucci, MD: Oncology Institute of Bari: Study Director: Domenico Galetta, MD "Giovanni Paolo II" Oncology Instutute Medical Oncology Dept. ... Division of Medical Oncology & Breast Unit, Ospedale “Vito Fazzi”, Lecce, Italy. Tumors invading or abutting major blood vessels (based on radiologist assessment), Evidence of brain metastases not previously treated with RT (or any loco-regional treatment), Prior neoadjuvant or adjuvant chemotherapy within six months prior to study enrollment, Previous radiotherapy in the last month before study entry (except for radiotherapy to symptomatic bone sites at risk and not covered in the premises of measurable disease and assessable), A major surgery (including open biopsy) in the month preceding study enrollment or anticipation of a major surgery during the study, Unable or unwilling to take folic acid or vitamin B12 supplementation, Unable or unwilling to take corticosteroids, History of gastrointestinal fistula, perforation, or abscess, inflammatory bowel disease, or diverticulitis, Clinically significant third-space fluid collections, for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry, Need for taking or have recently taken (within 10 days of enrollment) aspirin (>325 mg/d), clopidogrel at doses >75 mg/d, dipyramidole, ticlopidine, or cilostazol. Volume 36, Supplement 3, Pages i, S1 … 7 Division of Medical Oncology, "Casa Sollievo della Sofferenza" Hospital, Medical Oncology Division "Vito Fazzi" Hospital, Division of Medical Oncology, "Buccheri-La Ferla" Hospital, Division of Medical Oncology, "La Maddalena" Hospital, Division of Medical Oncology, Castellaneta Hospital, Division of Medical Oncology "San Giuseppe Moscati Hospital", Clinical Trials Office, Department of Medical Sciences, Azienda ULSS 13. Giuseppe has 2 jobs listed on their profile. Over 25 years of experience in pharmaceutical and diagnostic research and clinical studies; worked as Senior Manager in Test Development and Head of Study Management for Integrated Health Care Solutions in the area of Oncology, Infectious Diseases and Sepsis for Boehringer Mannheim, Germany and Roche Diagnostics, Rotkreuz, Switzerland; prior to joining Roche he worked at the Max Planck … Master Sina ft Balti – Clandestino. September 21, 2016. Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number): Why Should I Register and Submit Results? The total sample to be enrolled for this study will then be increased to 118 patients [(49 +49) +20%)], Difference in terms of quality of life (QOL) between treatment arms [ Time Frame: Treatment efficacy will be evaluated at baseline and every 3 cycles during chemo period and every two months during the maintenance phase ], treatment activity in terms of response rate [ Time Frame: Two year ], toxicity evaluation [ Time Frame: Two years ], Evaluation of QoL across time [ Time Frame: Two years ], Written informed consent(as approved by the local Ethical Committee), Histological type consisting mainly of non-squamous histology defined preferably with stage IV metastatic disease or stage IIIB in the presence of supraclavicular lymph nodes according to the parameters of TNM 7th Ed, not amenable to curative therapy, Adequate hepatic, coagulative and renal function, Mixed NSCLC tumors or mixed adenosquamous carcinomas with a predominant squamous component histotype (NSCLC and SCLC) or adenosquamous forms, with predominant squamous component. This year the event will feature 60 speakers all from different Mediterranean countries and all specialising in different aspects relating to gastrointestinal tumours. Please remove one or more studies before adding more. Enter words / phrases / DOI / ISBN / authors / keywords / etc. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01303926. Galetta D, Cinieri S, Pisconti S, Gebbia V, Morabito A, Borsellino N, Maiello E, Febbraro A, Catino A, Rizzo P, Montrone M, Misino A, Logroscino A, Rizzi D, Di Maio M, Colucci G. Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III Randomized Trial. Published online published online before print  (Clinical Trial), Induction Pemetrexed and Cisplatin Followed by Pemetrexed as Maintenance vs Carboplatin-paclitaxel and Bevacizumab Followed by Bevacizumab as Maintenance:Multicenter Randomized Phase III Study in Patients With Advanced Non-Squamous Non Small-cell Lung Cancer: a Quality of Life Oriented Phase III Trial of the GOIM, Active Comparator: Cisplatin and Pemetrexed, Active Comparator: Carboplatin paclitaxel bevacizumab, 18 Years to 70 Years   (Adult, Older Adult), Division of Medical Oncology, "Fatebenefratelli" Hospital, Division of Medical Oncology, "Sen. Perrino" Hospital, Brindisi, Italy. Giuseppe Colucci MD. CancerLinQ JCO Global Oncology ASCO Career Center To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. 8 Department of Clinical and Experimental Oncology, Medical Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy. “A phase I trial of radiochemotherapy with gemcitabine in advanced bladder cancer or local recurrence”Annals of oncology – Vol 15 … Single-agent gemcitabine became standard first-line treatment for advanced pancreatic cancer after demonstration of superiority compared with fluorouracil. (Oncology Institute Regina Elena, Roma). Patients are also excluded if they cannot hold nonsteroidal anti-inflammatory agents, other than prophylactic therapy with low-dose aspirin, for a 5-day period during each cycle (8-day period for long-acting agents, such as piroxicam), Need for taking or have recently taken (within 10 days of enrollment) fulldose oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes.